Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Aldeyra Therapeutics

03/08/2026 23:31

Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Aldeyra Therapeutics Inc is for a loss of 9 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Aldeyra Therapeutics Inc is $5.00, about 226.8% above its last closing price of $1.53
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.12
-0.10
-0.06
Beat
38.5
Dec. 31 2026
-0.15
-0.17
-0.10
Beat
40.5
Sep. 30 2025
-0.20
-0.24
-0.13
Beat
46.9​
Jun. 30 2025
-0.23
-0.24
-0.16
Beat
34.2
​​Mar. 31 2025
-0.30
-0.28
-0.17
Beat
39.3
Dec. 31 2024
-0.26
-0.23
-0.27
Missed
-19.9​
Sep. 30 2024
-0.26
-0.25
-0.25
Met
-1.2
Jun. 30 2024
-0.14
-0.14
-0.28
Missed
-97.5
This summary was machine generated August 3 at 22:31 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)